Cargando…

Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

Detalles Bibliográficos
Autores principales:	Sestini, Stefano, Boeri, Mattia, Marchiano, Alfonso, Pelosi, Giuseppe, Galeone, Carlotta, Verri, Carla, Suatoni, Paola, Sverzellati, Nicola, Vecchia, Carlo La, Sozzi, Gabriella, Pastorino, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800273/ https://www.ncbi.nlm.nih.gov/pubmed/31666934 http://dx.doi.org/10.18632/oncotarget.27256

Ejemplares similares

Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
por: Sestini, Stefano, et al.
Publicado: (2015)

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
por: Mensah, Mavis, et al.
Publicado: (2017)

Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients
por: Fortunato, Orazio, et al.
Publicado: (2014)

Inflammatory status and lung function predict mortality in lung cancer screening participants
por: Pastorino, Ugo, et al.
Publicado: (2018)

MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature
por: Fortunato, Orazio, et al.
Publicado: (2016)

Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations()
por: Hu, Jiangting, et al.
Publicado: (2015)

Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting
por: Montomoli, Emanuele, et al.
Publicado: (2021)

Pleural plaques in lung cancer screening by low-dose computed tomography: prevalence, association with lung cancer and mortality
por: Silva, Mario, et al.
Publicado: (2017)

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers
por: Verri, Carla, et al.
Publicado: (2017)

Feasibility and Safety of Lung Cancer Screening and Prevention Program During the COVID-19 Pandemic
por: Milanese, Gianluca, et al.
Publicado: (2021)

Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy
por: Apolone, Giovanni, et al.
Publicado: (2020)

Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR
por: Conte, Davide, et al.
Publicado: (2015)

Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening
por: Fortunato, Orazio, et al.
Publicado: (2022)

Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
por: Pastorino, U, et al.
Publicado: (2019)

Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
por: Pastorino, U, et al.
Publicado: (2019)

Author Correction: Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
por: Moro, Massimo, et al.
Publicado: (2018)

Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
por: Moro, Massimo, et al.
Publicado: (2017)

Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer
por: Fortunato, Orazio, et al.
Publicado: (2019)

C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis
por: Leuzzi, Giovanni, et al.
Publicado: (2017)

Volumetric Measurements in Lung Cancer Screening Reduces Unnecessary Low-Dose Computed Tomography Scans: Results from a Single-Center Prospective Trial on 4119 Subjects
por: Milanese, Gianluca, et al.
Publicado: (2022)

Therapeutic Use of MicroRNAs in Lung Cancer
por: Fortunato, Orazio, et al.
Publicado: (2014)

Effect of Tobacco Smoking Cessation on C-Reactive Protein Levels in A Cohort of Low-Dose Computed Tomography Screening Participants
por: Gallus, Silvano, et al.
Publicado: (2018)

Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk
por: Fortunato, Orazio, et al.
Publicado: (2019)

Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis
por: Milione, Massimo, et al.
Publicado: (2020)

Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval
por: Silva, Mario, et al.
Publicado: (2020)

Fully automated calcium scoring predicts all-cause mortality at 12 years in the MILD lung cancer screening trial
por: Sabia, Federica, et al.
Publicado: (2023)

Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320
por: Pontis, Francesca, et al.
Publicado: (2021)

Automated Coronary Artery Calcium and Quantitative Emphysema in Lung Cancer Screening: Association With Mortality, Lung Cancer Incidence, and Airflow Obstruction
por: Balbi, Maurizio, et al.
Publicado: (2023)

Extracellular vesicles from subjects with COPD modulate cancer initiating cells phenotype through HIF-1α shuttling
por: Petraroia, Ilaria, et al.
Publicado: (2023)

Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction
por: Fortunato, O, et al.
Publicado: (2014)

MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway
por: Moro, Massimo, et al.
Publicado: (2022)

Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance
por: Gatti, Laura, et al.
Publicado: (2022)

YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes
por: Lorenzetto, Erica, et al.
Publicado: (2014)

Circulating tumor cells and DNA as liquid biopsies
por: Heitzer, Ellen, et al.
Publicado: (2013)

Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133(+) Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer
por: Moro, Massimo, et al.
Publicado: (2015)

Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients
por: Benini, Stefania, et al.
Publicado: (2018)

New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies
por: Larrea, Erika, et al.
Publicado: (2016)

Circulating platelets as liquid biopsy sources for cancer detection
por: Antunes‐Ferreira, Mafalda, et al.
Publicado: (2020)

A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer
por: Gargiuli, Chiara, et al.
Publicado: (2022)

Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
por: Ye, Qianwei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_buultdllr6d1dllnfrtkhc0lmf